X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Orchid Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs ORCHID PHARMA LTD - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA ORCHID PHARMA LTD SUN PHARMA/
ORCHID PHARMA LTD
 
P/E (TTM) x 34.4 -0.1 - View Chart
P/BV x 2.7 0.1 2,375.0% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 SUN PHARMA   ORCHID PHARMA LTD
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
ORCHID PHARMA LTD
Sep-13
SUN PHARMA/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs701194 361.1%   
Low Rs43335 1,237.7%   
Sales per share (Unadj.) Rs110.4276.5 39.9%  
Earnings per share (Unadj.) Rs11.0-79.2 -13.9%  
Cash flow per share (Unadj.) Rs17.2-43.5 -39.7%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs158.853.9 294.4%  
Shares outstanding (eoy) m2,399.2670.45 3,405.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x5.10.4 1,239.7%   
Avg P/E ratio x51.6-1.4 -3,572.2%  
P/CF ratio (eoy) x32.9-2.6 -1,248.5%  
Price / Book Value ratio x3.62.1 168.2%  
Dividend payout %18.20-   
Avg Mkt Cap Rs m1,360,0218,067 16,860.1%   
No. of employees `00017.82.8 635.3%   
Total wages/salary Rs m53,6712,527 2,123.9%   
Avg. sales/employee Rs Th14,890.96,956.1 214.1%   
Avg. wages/employee Rs Th3,017.1902.5 334.3%   
Avg. net profit/employee Rs Th1,480.6-1,993.0 -74.3%   
INCOME DATA
Net Sales Rs m264,89519,477 1,360.0%  
Other income Rs m8,388407 2,059.8%   
Total revenues Rs m273,28219,884 1,374.4%   
Gross profit Rs m56,0811,103 5,086.3%  
Depreciation Rs m14,9982,519 595.4%   
Interest Rs m5,1765,227 99.0%   
Profit before tax Rs m44,295-6,236 -710.3%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-9,505511 -1,860.1%   
Tax Rs m8,452-125 -6,750.7%   
Profit after tax Rs m26,338-5,580 -472.0%  
Gross profit margin %21.25.7 374.0%  
Effective tax rate %19.12.0 950.4%   
Net profit margin %9.9-28.7 -34.7%  
BALANCE SHEET DATA
Current assets Rs m316,35911,014 2,872.3%   
Current liabilities Rs m198,64332,060 619.6%   
Net working cap to sales %44.4-108.1 -41.1%  
Current ratio x1.60.3 463.6%  
Inventory Days Days9595 99.9%  
Debtors Days Days10834 320.9%  
Net fixed assets Rs m213,17829,440 724.1%   
Share capital Rs m2,399705 340.6%   
"Free" reserves Rs m378,6062,043 18,535.5%   
Net worth Rs m381,0063,800 10,026.7%   
Long term debt Rs m17,7219,018 196.5%   
Total assets Rs m643,02846,510 1,382.5%  
Interest coverage x9.6-0.2 -4,949.4%   
Debt to equity ratio x02.4 2.0%  
Sales to assets ratio x0.40.4 98.4%   
Return on assets %4.9-0.8 -644.8%  
Return on equity %6.9-146.9 -4.7%  
Return on capital %10.0-3.7 -268.4%  
Exports to sales %037.9 0.0%   
Imports to sales %022.6 0.0%   
Exports (fob) Rs mNA7,378 0.0%   
Imports (cif) Rs mNA4,406 0.0%   
Fx inflow Rs m40,8167,513 543.3%   
Fx outflow Rs m30,1435,649 533.6%   
Net fx Rs m10,6731,865 572.4%   
CASH FLOW
From Operations Rs m39,0721,682 2,323.3%  
From Investments Rs m-33,708-9,860 341.9%  
From Financial Activity Rs m-15,3936,644 -231.7%  
Net Cashflow Rs m-7,359-1,535 479.4%  

Share Holding

Indian Promoters % 63.7 32.3 197.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 4.6 111.5%  
FIIs % 23.0 3.3 697.0%  
ADR/GDR % 0.0 4.6 -  
Free float % 8.3 55.3 15.0%  
Shareholders   133,026 84,811 156.8%  
Pledged promoter(s) holding % 0.5 54.9 1.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   ALKEM LABORATORIES  PLETHICO PHARMA  WOCKHARDT LTD.  TORRENT PHARMA  FRESENIUS KABI ONCO.  

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 190 Points Higher; Consumer Durable and Healthcare Stocks Witness Buying(Closing)

After trimming sharp losses in the afternoon session, Indian share markets continued to witness buying interest and ended the day on a positive note.

Related Views on News

AJANTA PHARMA Surges by 6%; BSE HEALTHCARE Index Up 2.0% (Market Updates)

Dec 11, 2018 | Updated on Dec 11, 2018

AJANTA PHARMA share price has surged by 6% and its current market price is Rs 1,077. The BSE HEALTHCARE is up by 2.0%. The top gainers in the BSE HEALTHCARE Index are AJANTA PHARMA (up 5.6%) and SUN PHARMA (up 5.5%). The top losers are DR. LAL PATHLABS LTD (down 0.3%) and THYROCARE TECHNOLOGIES (down 0.4%).

SUN PHARMA Surges by 6%; BSE HEALTHCARE Index Up 2.0% (Market Updates)

Dec 11, 2018 | Updated on Dec 11, 2018

SUN PHARMA share price has surged by 6% and its current market price is Rs 422. The BSE HEALTHCARE is up by 2.0%. The top gainers in the BSE HEALTHCARE Index is SUN PHARMA (up 5.6%). The top losers are THYROCARE TECHNOLOGIES (down 0.1%) and APOLLO HOSPITALS (down 0.1%).

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Dec 11, 2018 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUN PHARMA WITH

MARKET STATS